Intermittent Theta Burst Stimulation, Neuroprotection, Parkinson Disease
Conditions
Brief summary
Intermittent theta burst stimulation (iTBS) is an emerging non-invasive neuron regulation technique, which is widely used in neuropsychiatry for a variety of diseases and is widely accepted by patients due to its non-invasive, operable and relatively precise localization. Combining the results of previous studies and our group's previous research, sixty qualified PD patients would be enrolled to conduct a prospective single-center randomized double-blind sham controlled clinical trial to verify the long-term curative effects of iTBS treatment protocol and explore the neuron-protection of iTBS on neuronal loss of PD patients.
Interventions
DEVICEintermittent theta burst stimulation
iTBS is a new form of excitatory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
DEVICEsham iTBS
The pseudo-stimulation device looks and sounds the same as the iTBS device
Sponsors
Ruijin Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Meet the revised clinical diagnostic criteria for Parkinson's disease of the Movement Disorder Society (MDS) International (2015 version). * aged \>20 years and \<80 years, regardless of gender. * 2 ≤ Hoehn-Yahr stage≤ 4. * Maintain medication stability during the study period. * Good compliance, written informed consent, and consent for long-term interventional treatment with iTBS.
Exclusion criteria
* Patients with severe neuropsychiatric disorders or previous history of severe neurological disorders (e.g., epilepsy, cerebrovascular accidents, etc.) or history of traumatic brain injury or brain surgery. * Patients with significant cognitive impairment (MMSE \< 24) or inability to complete questionnaires independently. * Prior treatment with TMS, DBS or SCS. * Severe physical illness and any physical illness that can precipitate epilepsy or intracranial hypertension, including cardiovascular and respiratory disease. * Have human implantable materials such as intracranial stents, pacemakers, coronary stents, cochlear implants, etc. * Are currently taking other investigational drugs. * Any other condition that the investigator deems unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Group differences of part 3 of Unified Parkinson Disease Rating Scale (UPDRS) changes | 28 weeks | Compare the changes in UPDRS scores from baseline to post-iTBS in the four intervention groups (UPDRS part3: range 0\ 72, higher score is related to a worse outcome). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Group differences of Berg Balance Scale (BBS) changes | 28 weeks | Compare the changes in BBS scores from baseline to post-iTBS in the four intervention groups (BBS: range 0\ 56, higher score is related to a better outcome). |
| Group differences of Hamilton depression scale-17 (HAMD-17) changes | 28 weeks | Compare the changes in HAMD-17 scores from baseline to post-iTBS in the four intervention groups (HAMD-17: range 0\ 38, higher score is related to a worse outcome). |
| Group differences of Hamilton Anxiety Scale (HAMA) changes | 28 weeks | Compare the changes in HAMA scores from baseline to post-iTBS in the four intervention groups (HAMA: range 0\ 64, higher score is related to a worse outcome). |
| Group differences of Mini-mental State Examination (MMSE) changes | 28 weeks | Compare the changes in MMSE scores from baseline to post-iTBS in the four intervention groups (MMSE: range 0\ 30, higher score is related to a better outcome). |
| Group differences of Hoehn-Yahr stage | 28 weeks | Compare the changes in Hoehn-Yahr stage from baseline to post-iTBS in the four intervention groups (H-Y stage: range 0\ 5, higher score is related to a worse outcome). |
| Group differences of 39-item Parkinson's Disease Questionnaire (PDQ-39) changes | 28 weeks | Compare the changes in PDQ-39 scores from baseline to post-iTBS in the four intervention groups (PDQ-39: range 0\ 156, higher score is related to a worse outcome). |
| Group differences of 16-item Sniffin' Sticks test (SS-16) changes | 28 weeks | Compare the changes in SS-16 scores from baseline to post-iTBS in the four intervention groups (SS-16: range 0\ 16, higher score is related to a better outcome). |
| Group differences of Wexner changes | 28 weeks | Compare the changes in Wexner scores from baseline to post-iTBS in the four intervention groups (Wexner: range 0\ 30, higher score is related to a worse outcome). |
| Group differences of adverse event | 28 weeks | Compare the adverse event in four intervention groups. |
| Group differences of Montreal Cognitive Assessment (MoCA) changes | 28 weeks | Compare the changes in MoCA scores from baseline to post-iTBS in the four intervention groups (MoCA: range 0\ 30, higher score is related to a better outcome). |
Countries
China
Contacts
Primary ContactJun Liu, Professor
Outcome results
None listed